| Stereochemistry | ABSOLUTE |
| Molecular Formula | C21H22FN3O5 |
| Molecular Weight | 415.4149 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 3 / 3 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(C)[C@]1(CC(=NO1)C2=C3C=CC=CC3=CC=N2)C(=O)N[C@H]4CC(=O)O[C@]4(O)CF
InChI
InChIKey=VYFGDLGHHBUDTQ-ZLGUVYLKSA-N
InChI=1S/C21H22FN3O5/c1-12(2)20(19(27)24-16-9-17(26)29-21(16,28)11-22)10-15(25-30-20)18-14-6-4-3-5-13(14)7-8-23-18/h3-8,12,16,28H,9-11H2,1-2H3,(H,24,27)/t16-,20+,21+/m0/s1
| Molecular Formula | C21H22FN3O5 |
| Molecular Weight | 415.4149 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 3 / 3 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Nivocasan (aka GS-9450) was discovered by LG Life Sciences and developed by Gilead Sciences. Nivocasan is an irreversible inhibitor of caspase 1, 8, and 9, and therefore able to prevent apoptosis. Nivocasan has been investigated as a treatment option for Hepatic fibrosis and Non-alcoholic steatohepatitis related to Hepatitis C infection. It had advanced to Phase II clinical trials before the development program was suspended.
Originator
Approval Year
Sourcing
Sample Use Guides
Patients with Human Chronic Hepatitis C virus (HCV) and suffering from nonalcoholic steatohepatitis (NASH) were administered up to 40 mg of Nivocasan orally once daily for 4 weeks followed by a four week period with no dosing.
Route of Administration:
Oral
